Focusing on blood, breast and lung cancers, our specialists deliver exciting findings from the latest phase III trials. They explain keys to predicting disease progression; illuminate the roles of new therapies, including bispecific antibodies and antibody-drug conjugates; and discuss serious adverse effects, such as cytokine release syndrome and pneumonitis. Learn about T-DXd (now the standard for nonresectable or metastatic HER2), tailoring lung cancer management through neoadjuvant therapies, and more. Bonus: practical considerations for matching patients to treatment plans.
John Muir Health Presenters:
Published
December 16, 2022
Created by
Related Presenters
